AG˹ٷ

STOCK TITAN

[144] ABBVIE INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.

The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.

AbbVie ha presentato un Form 144 segnalando la proposta di vendita di 42.370 azioni ordinarie tramite Morgan Stanley Smith Barney LLC, per un valore di mercato complessivo di $8.407.068,11. La segnalazione indica la data approssimativa di vendita 08/12/2025 e specifica che le azioni sono state acquisite tramite esercizio di opzioni su azioni il 08/12/2025 con pagamento in contanti.

La comunicazione precisa che la persona per conto della quale saranno vendute le azioni non ha venduto titoli nei tre mesi precedenti. Il documento riporta il numero totale di azioni in circolazione pari a 1.766.558.253, identifica il broker esecutore e la classe di titolo come azioni ordinarie. Non sono forniti ulteriori dettagli sulla transazione né sulle identità coinvolte.

AbbVie presentó un Form 144 informando sobre una propuesta de venta de 42.370 acciones ordinarias a través de Morgan Stanley Smith Barney LLC, por un valor de mercado agregado de $8.407.068,11. La presentación indica la fecha aproximada de la venta como 08/12/2025 y muestra que las acciones fueron adquiridas mediante ejercicio de opciones sobre acciones el 08/12/2025 con pago en efectivo.

El aviso señala que la persona a cuyo nombre se venderán las acciones no ha vendido valores en los últimos tres meses. La declaración incluye el número total de acciones en circulación, 1.766.558.253, e identifica al corredor ejecutor y la clase de valor como acciones ordinarias. No se aportan más detalles sobre la operación ni identidades.

վ� Form 144� 제출하여 Morgan Stanley Smith Barney LLC� 통해 보통� 42,370주를 매도하려� 계획� 보고했으�, � 시가 $8,407,068.11� 기재했습니다. 제출서에� 매도 예정일을 08/12/2025� 적시하고, 해당 주식� 주식매수선택� 행사08/12/2025� 취득되었� 지급은 ˳금으로 이루어졌다고 표기되어 있습니다.

해당 통지에는 주식� 매도� 자를 대신한 해당 인물� 지� 3개월 동안 어떠� 증권� 매도하지 않았�� 명시되어 있습니다. 제출서에� 발행주식 총수가 1,766,558,253주로 기재되어 있으�, 집행 중개인과 증권 종류� 보통주로 나타� 있습니다. 거래� 추가적인 맥락이나 관련자 신원은 제공되지 않았습니�.

AbbVie a déposé un Form 144 signalant une proposition de vente de 42 370 actions ordinaires via Morgan Stanley Smith Barney LLC, pour une valeur de marché globale de $8 407 068,11. Le dépôt indique la date approximative de vente 08/12/2025 et précise que les actions ont été acquises par exercice d'options sur actions le 08/12/2025 avec un paiement en è.

L'avis précise que la personne pour le compte de laquelle les actions seront vendues n'a vendu aucun titre au cours des trois derniers mois. Le document comprend le nombre total d'actions en circulation, 1.766.558.253, et identifie le courtier exécutant ainsi que la catégorie de titre comme actions ordinaires. Aucune information supplémentaire sur la transaction ou les identités n'est fournie.

AbbVie reichte ein Form 144 ein und meldete den geplanten Verkauf von 42.370 Stammaktien über Morgan Stanley Smith Barney LLC mit einem gesamten Marktwert von $8.407.068,11. Die Einreichung nennt das ungefähre Verkaufsdatum 08/12/2025 und gibt an, dass die Aktien am 08/12/2025 durch Ausübung von Aktienoptionen erworben wurden und die Zahlung in Bargeld erfolgte.

Die Mitteilung besagt, dass die Person, in deren Namen die Aktien verkauft werden sollen, in den vergangenen drei Monaten keine Wertpapiere verkauft hat. Die Meldung enthält die Gesamtanzahl der ausstehenden Aktien mit 1.766.558.253 und nennt den ausführenden Broker sowie die Wertpapierklasse als Stammaktien. Weitere Transaktionskontexte oder Identitäten werden nicht angegeben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, routine Form 144 reporting a stock option exercise and proposed sale of 42,370 shares.

This Form 144 documents a proposed sale via Morgan Stanley of 42,370 shares valued at $8.41M and notes acquisition by stock option exercise on the same date. The filing reports no sales in the past three months, and provides outstanding share count. From a market-impact perspective the filing is procedural: it signals a planned disposition following option exercise rather than an unusual market event. The disclosure is complete for the transaction details shown but lacks names or further context.

TL;DR: Compliance-focused disclosure showing an option exercise and proposed sale; governance implications are routine.

The form affirms the seller represents no undisclosed material adverse information and records the broker, class, and payment method as cash. It shows the acquisition and proposed sale occurring on 08/12/2025. The absence of other recent sales simplifies aggregation requirements. For governance review, the filing appears to meet Rule 144 procedural content requirements but does not identify the filing individual's role or relationship beyond a generic field, leaving limited governance insight.

AbbVie ha presentato un Form 144 segnalando la proposta di vendita di 42.370 azioni ordinarie tramite Morgan Stanley Smith Barney LLC, per un valore di mercato complessivo di $8.407.068,11. La segnalazione indica la data approssimativa di vendita 08/12/2025 e specifica che le azioni sono state acquisite tramite esercizio di opzioni su azioni il 08/12/2025 con pagamento in contanti.

La comunicazione precisa che la persona per conto della quale saranno vendute le azioni non ha venduto titoli nei tre mesi precedenti. Il documento riporta il numero totale di azioni in circolazione pari a 1.766.558.253, identifica il broker esecutore e la classe di titolo come azioni ordinarie. Non sono forniti ulteriori dettagli sulla transazione né sulle identità coinvolte.

AbbVie presentó un Form 144 informando sobre una propuesta de venta de 42.370 acciones ordinarias a través de Morgan Stanley Smith Barney LLC, por un valor de mercado agregado de $8.407.068,11. La presentación indica la fecha aproximada de la venta como 08/12/2025 y muestra que las acciones fueron adquiridas mediante ejercicio de opciones sobre acciones el 08/12/2025 con pago en efectivo.

El aviso señala que la persona a cuyo nombre se venderán las acciones no ha vendido valores en los últimos tres meses. La declaración incluye el número total de acciones en circulación, 1.766.558.253, e identifica al corredor ejecutor y la clase de valor como acciones ordinarias. No se aportan más detalles sobre la operación ni identidades.

վ� Form 144� 제출하여 Morgan Stanley Smith Barney LLC� 통해 보통� 42,370주를 매도하려� 계획� 보고했으�, � 시가 $8,407,068.11� 기재했습니다. 제출서에� 매도 예정일을 08/12/2025� 적시하고, 해당 주식� 주식매수선택� 행사08/12/2025� 취득되었� 지급은 ˳금으로 이루어졌다고 표기되어 있습니다.

해당 통지에는 주식� 매도� 자를 대신한 해당 인물� 지� 3개월 동안 어떠� 증권� 매도하지 않았�� 명시되어 있습니다. 제출서에� 발행주식 총수가 1,766,558,253주로 기재되어 있으�, 집행 중개인과 증권 종류� 보통주로 나타� 있습니다. 거래� 추가적인 맥락이나 관련자 신원은 제공되지 않았습니�.

AbbVie a déposé un Form 144 signalant une proposition de vente de 42 370 actions ordinaires via Morgan Stanley Smith Barney LLC, pour une valeur de marché globale de $8 407 068,11. Le dépôt indique la date approximative de vente 08/12/2025 et précise que les actions ont été acquises par exercice d'options sur actions le 08/12/2025 avec un paiement en è.

L'avis précise que la personne pour le compte de laquelle les actions seront vendues n'a vendu aucun titre au cours des trois derniers mois. Le document comprend le nombre total d'actions en circulation, 1.766.558.253, et identifie le courtier exécutant ainsi que la catégorie de titre comme actions ordinaires. Aucune information supplémentaire sur la transaction ou les identités n'est fournie.

AbbVie reichte ein Form 144 ein und meldete den geplanten Verkauf von 42.370 Stammaktien über Morgan Stanley Smith Barney LLC mit einem gesamten Marktwert von $8.407.068,11. Die Einreichung nennt das ungefähre Verkaufsdatum 08/12/2025 und gibt an, dass die Aktien am 08/12/2025 durch Ausübung von Aktienoptionen erworben wurden und die Zahlung in Bargeld erfolgte.

Die Mitteilung besagt, dass die Person, in deren Namen die Aktien verkauft werden sollen, in den vergangenen drei Monaten keine Wertpapiere verkauft hat. Die Meldung enthält die Gesamtanzahl der ausstehenden Aktien mit 1.766.558.253 und nennt den ausführenden Broker sowie die Wertpapierklasse als Stammaktien. Weitere Transaktionskontexte oder Identitäten werden nicht angegeben.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does AbbVie's (ABBV) Form 144 report?

The Form 144 reports a proposed sale of 42,370 shares of common stock valued at $8,407,068.11 through Morgan Stanley Smith Barney LLC.

When is the approximate sale date listed on the ABBV Form 144?

The filing lists the approximate date of sale as 08/12/2025.

How were the shares acquired according to the Form 144?

The shares were acquired by a stock option exercise on 08/12/2025, with payment made in cash.

Does the Form 144 show any other sales in the past three months for ABBV?

No. The filing explicitly states Nothing to Report for securities sold during the past three months.

Which broker will handle the proposed ABBV share sale?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, New York, NY.
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Latest News

ABBV Latest SEC Filings

ABBV Stock Data

350.91B
1.76B
0.11%
74.95%
0.88%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
NORTH CHICAGO